VanEck Biotech ETF BBH
Strategy
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U.S. Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Ticker | Name | Share Class Type | Investment Status | Morningstar Rating for Funds Overall | Medalist Rating Overall | Inception Date | Total Net Assets for Share Class | Adjusted Expense Ratio | Fee Level Distribution | Minimum Initial Investment | 1-Year Net Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|
BBH | VanEck Biotech ETF | ETF | Open | — | — | 0.350% | — | — | — | ||
BBH | VanEck Biotech ETF | ETF | Open | $524.56M | 0.350% | — | — | $14.90M |